Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable profitability ...

Despite Jalen Hurts' success on the game's biggest stage, the Philadelphia Eagles star isn't getting any credit from Chase ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like Ozempic.

During a conversation with senior writer @EdEastonJr, retired NFL WR Steve Sanders discussed the potential of a #Chiefs vs. #Eagles Super Bowl rematch ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

Since becoming the starting quarterback of the Eagles in 2021, Hurts has gone 45-17 as a starting quarterback and has been an ...

Happy birthday, Jonathan Vilma. The Super Bowl-winning linebacker wasn't in New Orleans as long as you may think, but he made every minute count.

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

It can occur for so many reasons, from natural aging to hormonal causes to illness. No matter the culprit, Hims can help. The brand offers doctor-trusted solutions that are proven to deliver ...

While Hims & Hers offers Zepbound for $1,899 per month, Eli Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. HealthDay News — The telehealth company Hims ...

Hims & Hers now provides access to Zepbound, a brand-name version of the drug tirzepatide, for $1,899 per month. HealthDay News — The telehealth company Hims & Hers Health is expanding its weight-loss ...